glaucoma

Glaucoma may not be the disease you think it is
Glaucoma may not be the disease you think it isClinicians continue to explore the relationship between IOP and cerebrospinal fluid pressure in glaucoma.
Aqueous drainage tube provides trabeculectomy-like efficacyIn a study including 23 eyes with a transscleral micro-lumen aqueous drainage tube after failing maximum tolerated medication, reductions in the mean IOP were observed as well as in the mean number of medications per day.
Multiple next-generation stents lead to better IOP controlThe use of multiple second-generation stent systems led to a 20% or higher reduction in IOP in a group of patients with mild-to-moderate, open-angle glaucoma.
Cyclophotocoagulation shows safety in glaucoma case seriesCharles L. Harris, MD, reviews safety and efficacy rates in a glaucoma case series after adding a proprietary laser system with probe to the surgical armamentarium.
CO2 laser-assisted procedure showing long-term efficacy, safety
CO2 laser-assisted procedure showing long-term efficacy, safetyCO2 laser-assisted sclerectomy performed with a proprietary laser system is a simplified filtration procedure that is showing good IOP-lowering efficacy and safety in eyes followed to 5 years.
Second pivotal trial confirms IOP-lowering efficacy of first-in-class agentResults from a second pivotal trial investigating latanoprostene bunod 0.024% (LBN) are consistent with another identically designed study showing that not only is LBN non-inferior to timolol maleate 0.5% for lowering IOP, but it has significantly greater efficacy.
Novel gelatin stent works effectively as stand-alone procedureOne-year results are reviewed for use of a novel ab-interno gelatin stent as a stand-alone procedure for patients with mild-to-moderate primary open-angle glaucoma.
New dual blade can help surgeons lower IOPA new trabecular meshwork excision blade takes a new approach in IOP reduction.
Bimatoprost sustained-release implants: Potential new pathway for glaucoma patientsThe bimatoprost sustained-release implant (bimatoprost SR, Allergan) improves compliance for patients with problematic compliance with topical IOP-lowering glaucoma drugs and controlled the IOP for 6 months after injection.
Ceeable aims to be the next gold standard in visual fields
Ceeable aims to be the next gold standard in visual fieldsCeeable, a web-based, mobile digital technology designed to detect early-stage eye diseases—an innovation that can help shape 21st century medicine—was awarded third place in the American Medical Association’s inaugural Healthier Nation Innovation Challenge.